RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays

Area of Science:

• Molecular Biology
• Pharmacology
• Genetics

Background:

• RNA splicing is crucial for generating mature RNA molecules.
• Aberrant RNA splicing underlies various diseases, creating a need for therapeutic interventions.
• RNA splicing modifiers represent a novel pharmacological strategy.

Purpose of the Study:

• To review existing RNA splicing modifiers.
• To discuss methods for discovering novel splicing modifiers.
• To explore the chemical diversity of small-molecule splicing modifiers.

Main Methods:

• Literature review of approved and experimental splicing modifiers.
• Summary of high-throughput screening techniques for identifying new modifiers.
• Analysis of the chemical structures and properties of small-molecule splicing modulators.

Main Results:

• Several antisense oligonucleotide splicing modifiers are FDA-approved for conditions like SMA and DMD.
• Small molecules, such as risdiplam, are emerging as effective splicing regulators.
• Novel RNA-targeting modifiers can address previously undruggable genetic targets.

Conclusions:

• RNA splicing modulation is a viable therapeutic modality for genetic diseases and potentially infectious diseases.
• Small molecules are key components in the development of RNA splicing-targeting drugs.
• Further development of splicing modifiers will expand therapeutic options and research tools.